P358 Long-term clinical outcomes of intestinal Behçet's disease: a 30-year cohort study at a tertiary hospital in South Korea. (30th January 2023)
- Record Type:
- Journal Article
- Title:
- P358 Long-term clinical outcomes of intestinal Behçet's disease: a 30-year cohort study at a tertiary hospital in South Korea. (30th January 2023)
- Main Title:
- P358 Long-term clinical outcomes of intestinal Behçet's disease: a 30-year cohort study at a tertiary hospital in South Korea
- Authors:
- Park, J
Park, S J
Park, J J
Kim, T I
Kim, W H
Cheon, J H - Abstract:
- Abstract: Background: Long-term clinical data on intestinal Behçet's disease (BD) are scarce because of the rarity of this disease, and many issues remain unresolved due to the difficulty in performing a well-designed clinical trial or epidemiologic study. We aimed to investigate the long-term clinical outcomes of patients with intestinal BD with a 30-year cohort study at a tertiary hospital in South Korea, a hospital with the largest number of patients with intestinal BD worldwide. Additionally, we aimed to identify factors that could predict various clinical outcomes, including anti-tumor necrosis factor-alpha (anti-TNF-α) agent use, intestinal surgery, hospitalization, and emergency room visits. Methods: A cohort of 780 patients with intestinal BD between 1997 and 2021 was investigated to determine the long-term clinical outcomes and prognostic factors at the inflammatory bowel disease Clinic of Severance Hospital, Seoul, Korea. Results: During the median follow-up period of 12.7 ± 7.2 years, 5-aminosalicylic acids, corticosteroids, immunomodulators, and anti-tumor necrosis factor-alpha (TNF-α) agents were required in 94.9%, 67.2%, 43.8%, and 14.6% of the patients, respectively. The cumulative rates of anti-TNF-α use were 3.7%, 7.5%, 8.5%, 12.1%, 17.6%, and 24.0%, and that of abdominal surgery were 5.7%, 10.9%, 12.6%, 16.5%, 21.6%, and 28.3%, at 1, 3, 5, 10, 20, and 30 years, respectively, after the initial diagnosis of intestinal BD. The cumulative rates ofAbstract: Background: Long-term clinical data on intestinal Behçet's disease (BD) are scarce because of the rarity of this disease, and many issues remain unresolved due to the difficulty in performing a well-designed clinical trial or epidemiologic study. We aimed to investigate the long-term clinical outcomes of patients with intestinal BD with a 30-year cohort study at a tertiary hospital in South Korea, a hospital with the largest number of patients with intestinal BD worldwide. Additionally, we aimed to identify factors that could predict various clinical outcomes, including anti-tumor necrosis factor-alpha (anti-TNF-α) agent use, intestinal surgery, hospitalization, and emergency room visits. Methods: A cohort of 780 patients with intestinal BD between 1997 and 2021 was investigated to determine the long-term clinical outcomes and prognostic factors at the inflammatory bowel disease Clinic of Severance Hospital, Seoul, Korea. Results: During the median follow-up period of 12.7 ± 7.2 years, 5-aminosalicylic acids, corticosteroids, immunomodulators, and anti-tumor necrosis factor-alpha (TNF-α) agents were required in 94.9%, 67.2%, 43.8%, and 14.6% of the patients, respectively. The cumulative rates of anti-TNF-α use were 3.7%, 7.5%, 8.5%, 12.1%, 17.6%, and 24.0%, and that of abdominal surgery were 5.7%, 10.9%, 12.6%, 16.5%, 21.6%, and 28.3%, at 1, 3, 5, 10, 20, and 30 years, respectively, after the initial diagnosis of intestinal BD. The cumulative rates of hospitalization were 11.8%, 21.9%, 27.9%, 38.8%, 54.4%, and 74.8% and that of emergency room visits were 10.0%, 19.8%, 22.7%, 31.6%, 50.0%, and 65.0% at 1, 3, 5, 10, 20, 30 years. Older age at primary diagnosis, previous appendectomy history, higher disease activity index for intestinal Behçet's disease score, systemic BD, multiple intestinal ulcers, deep intestinal ulcers, higher C-reactive protein, lower hemoglobin, and lower albumin levels were associated with poor prognosis. Married status, higher body mass index, oral ulceration, and arthritis were negatively associated with a poor prognosis. Conclusion: The data on the long-term clinical outcomes of intestinal BD and their prognostic factors could guide physicians for adequate patient monitoring and optimizing individualized treatments. … (more)
- Is Part Of:
- Journal of Crohn's and colitis. Volume 17(2023)Supplement 1
- Journal:
- Journal of Crohn's and colitis
- Issue:
- Volume 17(2023)Supplement 1
- Issue Display:
- Volume 17, Issue 1 (2023)
- Year:
- 2023
- Volume:
- 17
- Issue:
- 1
- Issue Sort Value:
- 2023-0017-0001-0000
- Page Start:
- i493
- Page End:
- i493
- Publication Date:
- 2023-01-30
- Subjects:
- Inflammatory bowel diseases -- Periodicals
616.344005 - Journal URLs:
- http://www.journals.elsevier.com/journal-of-crohns-and-colitis/ ↗
http://ecco-jcc.oxfordjournals.org/content/9/3 ↗
http://www.elsevier.com/journals ↗ - DOI:
- 10.1093/ecco-jcc/jjac190.0488 ↗
- Languages:
- English
- ISSNs:
- 1873-9946
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 4965.651500
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 26863.xml